多拉韦林附加治疗HIV感染者病毒学失败与低水平病毒血症的疗效
研究评估在现有抗逆转录病毒治疗方案中附加多拉韦林对两类HIV感染者的疗效:近期病毒学反弹组(n=84)和长期低水平病毒血症组(n=39)。6个月后,近期失败组88%实现病毒学成功,低水平病毒血症组仅33%;疗效与基因型敏感性评分(GSS)密切相关,保留两种及以上活性药物的患者成功率更高。
要点
- 附加多拉韦林可在不改变全套方案的情况下 rescuing 病毒学控制。
- 近期病毒学反弹组6个月病毒学成功率达88%,低水平病毒血症组为33%。
- 疗效与GSS相关,保留≥2种活性药物者成功率更高。
核心结论
- 多拉韦林附加策略支持在不改变全套方案的情况下挽救病毒学控制,尤其当全套方案更换不可行且GSS有利时。
研究设计与样本
- 在现有抗逆转录病毒治疗方案中附加多拉韦林,不修改其他药物,纳入近期病毒学反弹组(n=84)和长期低水平病毒血症组(n=39)。
主要发现
- 6个月后,近期失败组88%的HIV感染者实现病毒学成功,低水平病毒血症组为33%。
- 疗效与基因型敏感性评分(GSS)密切相关,保留两种及以上活性药物的患者成功率更高。
- 多拉韦林耐药突变不常见,但在低水平病毒血症组更频繁出现。
- 治疗反应与CD4计数、最低点、病毒载量峰值或抑制持续时间无显著关联。
关键数值与推荐
- 近期病毒学反弹组6个月病毒学成功率为88%,低水平病毒血症组为33%。
- 疗效与GSS相关,方案保留≥2种活性药物者成功率更高。
临床怎么用
- 当全套方案更换不可行且GSS有利时,可考虑附加多拉韦林以挽救病毒学控制。
局限性
- 低水平病毒血症组样本量较小(n=39),可能影响结果稳定性。
- 多拉韦林耐药突变在低水平病毒血症组更常见,需关注耐药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with moderate plasma protein binding and good potential for anatomical sanctuary penetration. MATERIALS AND METHODS: Adding doravirine to existing antiretroviral therapy (ART) regimens has led to virological success in two groups of people living with HIV (PLWHIV): those with recent virological rebound (n = 84) and those with prolonged low-level viremia (LLV, n = 39). Doravirine was added without any modification to the other ART drugs. RESULTS: After 6 months, 88% of PLWHIV in the recent failure group had achieved virological success, compared to 33% of those in the LLV group. Efficacy was closely tied to the genotypic susceptibility score (GSS), with higher success rates in patients whose regimens retained two or more active drugs. Doravirine resistance mutations were uncommon but occurred more frequently in the LLV group. No significant associations were found between treatment response and CD4 count, nadir, VL zenith or duration of suppression. CONCLUSIONS: These findings support the use of doravirine add-on strategies to rescue virological control without changing the full regimen, particularly when a full regimen change is not feasible and when GSS is favourable. The study highlights the potential of doravirine in tailored salvage therapy strategies.
引用
- Calvez V, Charpentier C, Alidjinou EK, et al. Add-on efficacy of doravirine in PLWHIV with virological failure and low-level viremia. J Antimicrob Chemother. 2026. PMID: 42324920. doi:10.1093/jac/dkag191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。